Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02076009 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 569
- Enrollment target
NCT02076009 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 569 participants.
The verdict
NCT02076009, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 569 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 569 participants |
| Start Date | 2014-07-23 |
| Est. Completion | 2024-11-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02076009
The ClinicalTrials.gov registry entry for NCT02076009 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 569 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02076009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02076009 about?
NCT02076009 is a clinical study titled "A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma". The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.
What is the current status of trial NCT02076009?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 569 participants. The study started on 2014-07-23. Estimated completion is 2024-11-21.
What interventions are being tested in trial NCT02076009?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG).
Who is sponsoring clinical trial NCT02076009?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.